Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial - Wikidata - awgldk - TriplyDB

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

http://www.wikidata.org/entity/Q33750154

about

Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Medical treatment of renal cancer: new horizons Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study Brazilian data of renal cell carcinoma in a public university hospital Monitoring the vascular response and resistance to sunitinib in renal cell carcinoma in vivo with susceptibility contrast MRI.Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study.Combined GSTM1-Null, GSTT1-Active, GSTA1 Low-Activity and GSTP1-Variant Genotype Is Associated with Increased Risk of Clear Cell Renal Cell Carcinoma.Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy Post partial nephrectomy surveillance imaging: an evidence-based approach.Kidney cancer and 2014: is innovation really over?Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials.Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.Targeted therapy for renal cell carcinoma: focus on 2nd and 3rd line.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers.The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate.Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib.Individualized dosing with axitinib: rationale and practical guidance.Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety.Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma.[Therapy of recurrent or metastatic head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].The tyrosine-kinase inhibitor sunitinib targets vascular endothelial (VE)-cadherin: a marker of response to antitumoural treatment in metastatic renal cell carcinoma.Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition.Management of metastatic renal cell carcinoma - mini review.Immune consequences of anti-angiogenic therapyin renal cell carcinoma.

P2860

Q26744758-1A5DB1D0-5E75-4002-A91E-779B2F8D8C36 Q26751341-C6CA178A-1064-43AB-8189-6CC322A98667 Q26766240-184C3E25-1B57-48F2-BDCC-C7DAEC9668E6 Q28073174-7E8790FA-EEC9-4C57-9D56-98FCEE962B7A Q28547506-BCF77550-1A31-4158-B84C-63E2B7AAA745 Q31089209-025AD147-BCAA-42DE-B44B-9C2507095C6E Q32176092-64B66F55-BC8E-4D6E-A008-1929FA5C6D4F Q33431578-8AF5305F-F554-467F-83D8-0A66C7760D34 Q35044419-3371C74F-782E-41FF-8034-62401B61F285 Q35549876-012BE003-7420-49A6-B1F1-F9F356465140 Q36097289-27BC45C4-B41A-4000-9216-B6BC0A5F497B Q37290050-56DA3E48-D5E7-4001-9EDB-5E15BDDC2D06 Q37620907-9091C494-D206-4876-B704-AFA95AF60A4A Q38370142-5B5B1B5B-648E-4325-99E0-D8FB79747A92 Q38465870-A8893B49-E77A-4EA8-B343-AE248732D1D4 Q38514440-98A9A3CB-D72F-4625-A519-984B5EB888E1 Q38543085-81D56319-F5AB-4098-B9FD-989D4FF2C069 Q38648762-7DDFDE22-6286-48A4-AD8B-E571448D98D2 Q38653213-AE82F9B4-B7DF-433E-8CBD-7A0086DA956C Q38656760-DC858CF7-5E51-417D-A9BE-D2429BFE9BE7 Q38657787-D28FDD3B-DEE8-4CFF-8960-639295B7F4C5 Q38686066-A7A7FED7-8CA3-44DC-BC7E-29620BFBC15F Q38950573-38777BF4-3DEE-4E51-9C62-6DD4965817DD Q41735562-8FE4D890-22EC-489D-AF98-E9A0806A6866 Q42365081-05715977-5709-454A-B313-53E1FC367D3E Q45824477-929A1D9B-DBA0-4991-8E29-33E6A9527AD6 Q47271327-18493557-2BFC-4130-A467-3C24DB71E9DC Q47813600-0F295616-B13F-4627-965E-C711771E2003 Q48256655-36A0BCC0-AFA1-42DC-B27E-677B30B258A8 Q48528146-0073D21E-FB84-4D6C-A170-18E97FE7250E Q50049497-AC3CA6DA-9DD5-4F85-9049-6E4E8FA41366 Q51261062-1C3AC0DE-451F-4D0D-BB1D-2C314BD70FD5 Q51760779-2CAA7583-F33B-44AD-93C6-308508A544D9 Q52682465-3DA845A1-53FB-433E-AFDC-0034D4CD0904 Q53062408-D1003990-B468-43C2-9A57-469F40E5B00D Q53153700-AF69F609-2182-485D-A00B-C08BE8234E27 Q53848926-37843EF9-4A0A-4772-B910-AFEB840F1342 Q54981236-F32D252A-F939-470F-AD2B-15DEF28EE3B7

P2860

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

http://www.wikidata.org/entity/Q33750154

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Axitinib versus sorafenib in a ...... m a randomised phase III trial

@ast

Axitinib versus sorafenib in a ...... m a randomised phase III trial

@en

type

label

Axitinib versus sorafenib in a ...... m a randomised phase III trial

@ast

Axitinib versus sorafenib in a ...... m a randomised phase III trial

@en

prefLabel

Axitinib versus sorafenib in a ...... m a randomised phase III trial

@ast

Axitinib versus sorafenib in a ...... m a randomised phase III trial

@en

P1433

Q33750154-4F71FA41-282E-4254-92C2-1776D48BBAAF

P1476

Q33750154-6043FBF6-7210-44B0-AB01-D02AA8FD7509

P2093

Q33750154-057F1FB9-E3FD-4D5F-9937-4AC568E1F9F1

Q33750154-11CE8056-AF1C-4E02-90FF-C8C188836161

Q33750154-3DC3DA7D-CBF1-4A74-8C72-D434C7EEF43D

Q33750154-75F802AE-597E-4D4C-A1C1-52A136F1E7CB

Q33750154-78A3F956-8A99-444B-B2D4-81F2B1036727

Q33750154-88B582A7-9275-4750-96E6-979B8ED5A51E

Q33750154-8CC80C98-8557-4B80-AE84-730853475562

Q33750154-9B1C9307-7DAD-414A-B88A-7EB396AC4A8B

Q33750154-A0FBD5E0-019A-47C7-8EA5-86C089AC6362

Q33750154-ACF897D7-E7C7-4673-B87B-431C30320A59

P2860

Q33750154-074FAE22-7FB1-4A52-8F93-6491AC1E18D9

Q33750154-134A189A-861C-4EB5-A8A6-D3D158F01A85

Q33750154-22AC6C77-C4BE-44BA-8A38-8464CD13CCC5

Q33750154-301C75A9-D49E-461A-83B9-A97C2D6F90E5

Q33750154-3CF9B492-426E-4113-8205-64F8033DCBA3

Q33750154-56B8AD98-ED65-41BA-B78A-B558C1A5853E

Q33750154-7003D6F9-9406-4A08-8D6B-DE48F9ECBCDA

Q33750154-7BAA1DE9-8DFF-48B7-971B-A70C698E128F

Q33750154-812E4F76-0ECC-4F9A-B4F2-7545F4D5CFE3

Q33750154-8A288651-FED2-4A36-A36A-EC82C9735B2B

P2888

Q33750154-459BB5F3-FF4A-49F2-9302-1B128B2483F0

P304

Q33750154-AE406A50-F072-4340-9A94-27FB531D1C3F

P31

Q33750154-039FC2B7-3A1C-47D9-BAB6-61356C991DBC

P356

Q33750154-3EEDD8F3-19A1-41B7-AC6D-B2092E0E9EB0

P407

Q33750154-569833EA-BA4B-4A5A-87E5-060D62D3FFFE

P433

Q33750154-EFA1F5EB-EC50-442E-88C1-02CE36A3A54A

P478

Q33750154-4C8F9ADF-E611-4A1C-A001-A8046E45EACB

P50

Q33750154-BC637B90-1FC7-4792-BF66-1AA6C6351888

Q33750154-FE29E0A4-9F4E-45A9-9DA1-6CA20BE79AF3

P577

Q33750154-DAB2E1BB-7128-407E-B82B-0181635F04DA

P5875

Q33750154-08C79AC9-B377-46C4-AA97-AB9B46B597FD

P6179

Q33750154-CA205A53-15DE-421E-9FE8-1D248E57C429

P698

Q33750154-8A9ABBB8-C12C-42AF-B86A-74CFA22C5882

P921

Q33750154-D92E94BB-3CDE-4972-BEEE-F8E63D4B1C04

P932

Q33750154-487A38D0-B5FA-46AE-A983-B4262B7F222E

P356

P1433

British Journal of Cancer

P1476

Axitinib versus sorafenib in a ...... m a randomised phase III trial

@en

P2093

B Escudier

http://www.w3.org/2001/XMLSchema#string

B I Rini

http://www.w3.org/2001/XMLSchema#string

B Rosbrook

http://www.w3.org/2001/XMLSchema#string

E Porfiri

http://www.w3.org/2001/XMLSchema#string

G Kannourakis

http://www.w3.org/2001/XMLSchema#string

H Y Lim

http://www.w3.org/2001/XMLSchema#string

J I Clark

http://www.w3.org/2001/XMLSchema#string

J Tarazi

http://www.w3.org/2001/XMLSchema#string

L Cisar

http://www.w3.org/2001/XMLSchema#string

M Staehler

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced clear-cell renal-cell carcinoma

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.

P2888

P304

2821-2828

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.244

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

M. Dror Michaelson

P577

2014-05-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262303741

http://www.w3.org/2001/XMLSchema#string

P6179

1028556705

http://www.w3.org/2001/XMLSchema#string

P698

24823696

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4056058

http://www.w3.org/2001/XMLSchema#string